Skip to main content
EJNMMI Research
Fig. 8 | EJNMMI Research

Fig. 8

From: Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

Fig. 8

Morphology of GOT1 xenograft after 177Lu-octreotate exposure. This tumor was harvested from a mouse treated with a priming administration (2.5 MBq) followed by a subsequent dose (12.5 MBq) of 177Lu-octreotate 24 h later. Maximal reduction of tumor volume (67%) was noted 9 days after treatment. Thereafter, the tumor started to grow and was harvested on day 41 after the last injection. a The xenograft contained areas of fibrosis as well as areas of viable tumor cells (left). Viable tumor cells from the boxed area are shown at high magnification (right). Hematoxylin and eosin stain. b Tumor regression in xenografts is highlighted by staining for collagen (blue, Masson’s trichrome stain). c The NE differentiation of the xenograft was confirmed by positive staining for chromogranin A (brown). Viable tumor cells had a granular cytoplasmic staining as shown at high magnification (right panel). Scale bars equal 1 mm (left panel) and 50 μm (right panel)

Back to article page